EZH2 and malignant epithelial tumor of ovary: Epithelial ovarian cancer cell viability has been shown to be dependent on EZH2 expression, and therefore, EZH2 inhibition, is a promising targeted therapeutic strategy [46], highlighting the potential of miR-101 in the treatment of epithelial ovarian cancer.